Raymond James & Associates’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,757
| Closed | -$213K | – | 3926 |
|
|
2023
Q2 | $213K | Buy |
+6,757
| New | +$210K | ﹤0.01% | 3448 |
|
|
2023
Q1 | – | Sell |
-7,554
| Closed | -$229K | – | 4046 |
|
|
2022
Q4 | $229K | Sell |
7,554
-1,847
| -20% | -$55.6K | ﹤0.01% | 3372 |
|
|
2022
Q3 | $283K | Sell |
9,401
-5,410
| -37% | -$171K | ﹤0.01% | 3222 |
|
|
2022
Q2 | $410K | Buy |
14,811
+600
| +4% | +$17.1K | ﹤0.01% | 3033 |
|
|
2022
Q1 | $478K | Buy |
14,211
+34
| +0.2% | +$1.18K | ﹤0.01% | 3106 |
|
|
2021
Q4 | $599K | Sell |
14,177
-814
| -5% | -$36.3K | ﹤0.01% | 2955 |
|
|
2021
Q3 | $682K | Sell |
14,991
-10,077
| -40% | -$462K | ﹤0.01% | 2844 |
|
|
2021
Q2 | $1.23M | Buy |
25,068
+1,583
| +7% | +$75.8K | ﹤0.01% | 2454 |
|
|
2021
Q1 | $1.18M | Buy |
23,485
+2,956
| +14% | +$164K | ﹤0.01% | 2395 |
|
|
2020
Q4 | $1.05M | Buy |
20,529
+2,839
| +16% | +$135K | ﹤0.01% | 2314 |
|
|
2020
Q3 | $728K | Sell |
17,690
-976
| -5% | -$40.3K | ﹤0.01% | 2375 |
|
|
2020
Q2 | $781K | Buy |
18,666
+1,265
| +7% | +$49.9K | ﹤0.01% | 2323 |
|
|
2020
Q1 | $552K | Sell |
17,401
-978
| -5% | -$37.4K | ﹤0.01% | 2357 |
|
|
2019
Q4 | $777K | Sell |
18,379
-15,774
| -46% | -$585K | ﹤0.01% | 2433 |
|
|
2019
Q3 | $1.08M | Sell |
34,153
-1,359
| -4% | -$47.8K | ﹤0.01% | 2165 |
|
|
2019
Q2 | $1.28M | Sell |
35,512
-2,991
| -8% | -$103K | ﹤0.01% | 2074 |
|
|
2019
Q1 | $1.39M | Sell |
38,503
-21,464
| -36% | -$717K | ﹤0.01% | 2003 |
|
|
2018
Q4 | $1.69M | Sell |
59,967
-108,279
| -64% | -$3.59M | ﹤0.01% | 1764 |
|
|
2018
Q3 | $6.62M | Buy |
168,246
+50,942
| +43% | +$1.93M | 0.01% | 1052 |
|
|
2018
Q2 | $4.37M | Buy |
117,304
+39,858
| +51% | +$1.45M | 0.01% | 1278 |
|
|
2018
Q1 | $2.65M | Buy |
77,446
+6,840
| +10% | +$240K | ﹤0.01% | 1523 |
|
|
2017
Q4 | $2.31M | Buy |
70,606
+23,157
| +49% | +$725K | ﹤0.01% | 1597 |
|
|
2017
Q3 | $1.48M | Buy |
47,449
+11,322
| +31% | +$332K | ﹤0.01% | 1853 |
|
|
2017
Q2 | $1.01M | Sell |
36,127
-88,045
| -71% | -$2.29M | ﹤0.01% | 2022 |
|
|
2017
Q1 | $3.2M | Sell |
124,172
-21,650
| -15% | -$539K | 0.01% | 1249 |
|
|
2016
Q4 | $3.34M | Sell |
145,822
-2,745
| -2% | -$65.7K | 0.01% | 1196 |
|
|
2016
Q3 | $3.88M | Buy |
148,567
+131,890
| +791% | +$3.29M | 0.01% | 1077 |
|
|
2016
Q2 | $378K | Buy |
16,677
+490
| +3% | +$11.6K | ﹤0.01% | 2260 |
|
|
2016
Q1 | $355K | Sell |
16,187
-1,467
| -8% | -$33.5K | ﹤0.01% | 2230 |
|
|
2015
Q4 | $561K | Buy |
17,654
+7,215
| +69% | +$221K | ﹤0.01% | 1930 |
|
|
2015
Q3 | $291K | Buy |
+10,439
| New | +$364K | ﹤0.01% | 2145 |
|
Other funds holding SBIO
DC
SFS
NAM
Raymond James & Associates's SBIO Position: Q3 2023 in Review
Raymond James & Associates sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q3 2023, closing a stake of 6,757 shares — an estimated $213K sold.
Raymond James & Associates first reported a position in SBIO in Q3 2015 and held it in 31 quarters. The position peaked at $6.62M in Q3 2018. 36 funds tracked by Wall St. Rank hold SBIO as of Q3 2023.
- Raymond James & Associates reported no remaining ALPS Medical Breakthroughs ETF position as of Q3 2023 after selling out during the quarter.
- Raymond James & Associates sold 6,757 ALPS Medical Breakthroughs ETF shares in Q3 2023, an estimated $213K.
- Raymond James & Associates first reported a position in ALPS Medical Breakthroughs ETF in Q3 2015 and held it in 31 quarters.
- Raymond James & Associates's ALPS Medical Breakthroughs ETF position peaked at $6.62M in Q3 2018.
- 36 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q3 2023.
Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.